Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human immunodeficiency virus protease inhibitors

K Z Rana1, M N Dudley

  • 1Antiinfective Pharmacology Research Unit, University of Rhode Island College of Pharmacy, Roger Williams Medical Center, Providence 02908, USA.

Pharmacotherapy
|January 23, 1999
PubMed
Summary

Human immunodeficiency virus (HIV) protease inhibitors are crucial for suppressing viral replication by inhibiting essential viral enzymes. Optimal therapeutic strategies, including drug combinations and sequences, require further research to maximize treatment effectiveness.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.

Antimicrobial agents and chemotherapy·2022
Same author

Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients.

Antimicrobial agents and chemotherapy·2021
Same author

In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria.

Antimicrobial agents and chemotherapy·2001
Same author

SAR studies of anti-MRSA non-zwitterionic 3-heteroarylthiocephems.

The Journal of antibiotics·2001
Same author

Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time.

Current opinion in microbiology·2000
Same author

A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial.

Antimicrobial agents and chemotherapy·2000

Area of Science:

  • Virology
  • Pharmacology
  • Immunology

Background:

  • Human immunodeficiency virus (HIV) protease is essential for viral replication, cleaving polyproteins into functional components.
  • Protease inhibitors block this essential enzyme activity, preventing the production of infectious virions.
  • Combined with reverse transcriptase inhibitors, protease inhibitors offer potent suppression of HIV replication.

Purpose of the Study:

  • To review the role of HIV protease inhibitors in antiretroviral therapy.
  • To discuss the varying pharmacologic properties, toxicities, drug interactions, and resistance patterns of different protease inhibitors.
  • To highlight areas requiring further investigation for optimizing HIV treatment.

Main Methods:

  • Literature review of HIV protease inhibitor pharmacology and clinical applications.

Related Experiment Videos

  • Analysis of drug properties, including efficacy, safety, and resistance profiles.
  • Discussion of current challenges and future research directions in HIV treatment.

    • Main Results:

    • HIV protease inhibitors significantly suppress viral replication when used in combination therapy.
    • Individual protease inhibitors exhibit distinct pharmacokinetic profiles, toxicity, and drug interaction potentials.
    • Emergence of drug resistance is a critical factor influencing treatment outcomes.

    Conclusions:

    • HIV protease inhibitors are a cornerstone of effective antiretroviral therapy.
    • Careful consideration of individual drug characteristics and patient factors is necessary for selecting optimal treatment regimens.
    • Further research is needed to determine the best drug combinations, sequences, durability, and impact on immune reconstitution.